Email Updates

You are here

12 JULY 2019 VOLUME 20 ISSUE 26

Media Coverage

  • Johnson & Johnson is preparing to test an experimental HIV vaccine in the US and Europe in a move toward developing the first immunization against the deadly disease after decades of frustration. Some 3,800 men who have sex with men will receive a regimen of shots in a study that’s planned to be launched later this year, Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, said in an interview. The agency and the HIV Vaccine Trials Network of testing sites will collaborate with J&J’s Janssen unit on the effort.

    July 12, 2019
  • Since the AIDS epidemic exploded three decades ago, new HIV infection rates have fallen across the US. Yet for African American men, infection rates remain stubbornly high -- and, among Latino men, the rates are nudging upward.

    July 12, 2019
    US News & World Report
  • It took universal health care, political will and a health campaign designed to terrify the public, but nearly four decades into the HIV crisis, Australian researchers say the country is on a path toward making transmissions of the virus vanishingly rare.

    July 10, 2019
    New York Times
  • Two out of seven mice who received novel treatment and gene editing technology have had HIV eliminated from their bodies, reveals a ground-breaking study.

    July 10, 2019
  • That a drug does not work if patients do not take it, is a familiar phrase to those working in HIV, usually applied to treatment adherence. But the stalling decline in HIV incidence in the USA shows that the same is true of prevention and the use of pre-exposure prophylaxis (PrEP) as a public health approach—a preventive method will not have the desired public-health benefit if people are not using it.

    July 9, 2019
    Lancet HIV
  • Reaching individuals at high risk of acquiring HIV infection continues to pose a challenge to uptake of HIV pre-exposure prophylaxis (PrEP). A new study looked at PrEP clinical trials in sub-Saharan Africa, examining recruitment strategies to reach women at high risk of contracting HIV.

    July 9, 2019
    Contagion Live
  • Health officials say the HPV vaccine for 12 to 13-year-old boys, starting after the summer, will prevent 29,000 cancers in UK men in the next 40 years.

    July 9, 2019
  • Researchers have developed a new tool to pinpoint patients at high risk for contracting HIV to provide them preventive pre-exposure prophylaxis treatment, new research shows. This machine-learning algorithm, which was detailed July 5 in The Lancet HIV, predicted 2.2 percent of the 3.7 million Kaiser Permanente health system patients were at-risk or at high risk of contracting HIV within three years. Nearly half the patients identified by the algorithm went on to contract HIV.

    July 8, 2019
  • Zimbabwe has become the first country in the Sub-Saharan Africa region to complete the successful enrollment of participants who are taking part in the ongoing large-scale HIV vaccine efficacy trials which are currently underway on four continents, covering 12 countries with about 12,669 study participants on board.

    July 8, 2019
    The Herald
  • In research currently going on at the HIV Pathogenesis Programme (HPP) at the University of KwaZulu-Natal (UKZN), Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE) researchers are investigating whether ARVs treatment started within days of exposure to HIV could rid the body of the virus.

    July 7, 2019
    The Star
  • A team of researchers including infectious disease specialist Douglas S. Krakower, MD, of Beth Israel Deaconess Medical Center (BIDMC), has used machine learning to build an HIV risk prediction model to improve prescribing of the HIV-preventative medications among high risk populations. The scientists developed and validated automated algorithms that generate models that efficiently identify patients at increased risk for HIV infection based on electronic health records (EHR) data from a large healthcare system in Massachusetts.

    July 6, 2019
    Mirage News
  • The controversy surrounding Truvada in the United States isn't just about the drug's price tag -- it's about public health. HIV doctors and activists point out that when prices drop, so do the number of new HIV infections. For the past several years, doctors in the United States have watched enviously as other countries have approved generic versions of PrEP made by Mylan, Teva, and other generic drug companies. These cheaper generics have made it easier for governments to support large PrEP scale-up programs.

    July 3, 2019
    The Body
  • For the past several months, the US government has been lambasted by AIDS activists for ostensibly failing to seek royalties from Gilead Sciences (GILD) for an expensive HIV prevention pill sold by the company and therefore not using the funds to help thwart the virus.

    July 2, 2019
    STAT News
  • It’s half a century since the first known HIV-related death and two patients appear to have been cured of the virus. What does this mean for the 37 million still living with it?

    July 2, 2019
    The Guardian
  • When POZ magazine was founded in 1994, the US AIDS crisis was just reaching its peak. By the following year, half a million Americans had been diagnosed with the disease and nearly two thirds of them were already dead. And so, marrying the take-no-prisoners activism of ACT UP with the tenacious truth-seeking of a countercultural publication, POZ’s scrappy staff and cadre of writers armed themselves with the power of the pen against a potentially indefinite holocaust.

    July 1, 2019

Published Research